Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 6 of 6

Full-Text Articles in Medicine and Health Sciences

Assessment Of Three Acute Responses To Traumatic Brain Injury, Shoshana Fireworker Jan 2015

Assessment Of Three Acute Responses To Traumatic Brain Injury, Shoshana Fireworker

The Science Journal of the Lander College of Arts and Sciences

Traumatic brain injury has a devastating effect on millions worldwide each year. As yet, there are no methods which have been proven to improve recovery from the trauma. Current treatment protocols revolve around reducing secondary insult, such as hypoxia, hypotension, and cerebral edema, which raises intracranial pressure. The purpose of this study is to assess the efficacy of three responses to traumatic brain injury. Two of them, the administration of hypertonic saline and the administration of progesterone, are pharmacologic, while the third, the performance of a decompressive craniectomy, is surgically invasive. A number of original studies have been analyzed to …


Treating Acute Migraines: Triptans Vs. Antiemetics, Samuel Reisman Jan 2015

Treating Acute Migraines: Triptans Vs. Antiemetics, Samuel Reisman

The Science Journal of the Lander College of Arts and Sciences

Influential American medical organizations and publications have published guidelines for the treatment of acute migraine headaches that omit antiemetics, usually suggesting triptans as the first line of treatment. A review of the few comparative studies directly contrasting clinical outcomes of triptans and antiemetics in the treatment of acute migraines suggest that both treatment options are relatively equal in efficaciousness. The added burden of triptan usage, including an added risk of adverse effects and a high cost per dose, would seem to warrant an antiemetic-first approach to migraine treatment, as recommended by several international health communities. Possible reasons for the prominent …


Is There A Link Between Saturated Fat Intake And Alzheimer’S Disease?, Justin Konig Jan 2015

Is There A Link Between Saturated Fat Intake And Alzheimer’S Disease?, Justin Konig

The Science Journal of the Lander College of Arts and Sciences

Alzheimer’s disease is a neurodegenerative disease that causes dementia and ultimately death. Currently, there is no treatment available for this disease. The aging of the population will only increase the incidence of Alzheimer’s disease, making it ever more important to find an effective method of prevention. Dietary intervention is a practical and affordable method of intervention. The brain is a fat rich organ, and dietary fats are critical for proper development of the brain. A literature review was conducted to determine whether there is a link between saturated fat intake and Alzheimer’s disease. According to the literature reviewed, saturated fat …


Role Of Sigma-1 Receptors In Neurodegenerative Diseases, Linda Nguyen, Brandon P. Lucke-Wold, Shona A. Mookerjee, John Z. Cavendish, Matthew J. Robson, Anna L. Scandinaro, Rae Reiko Matsumoto Jan 2015

Role Of Sigma-1 Receptors In Neurodegenerative Diseases, Linda Nguyen, Brandon P. Lucke-Wold, Shona A. Mookerjee, John Z. Cavendish, Matthew J. Robson, Anna L. Scandinaro, Rae Reiko Matsumoto

Faculty Publications & Research of the TUC College of Pharmacy

Neurodegenerative diseases with distinct genetic etiologies and pathological phenotypes appear to share common mechanisms of neuronal cellular dysfunction, including excitotoxicity, calcium dysregulation, oxidative damage, ER stress and mitochondrial dysfunction. Glial cells, including microglia and astrocytes, play an increasingly recognized role in both the promotion and prevention of neurodegeneration. Sigma receptors, particularly the sigma-1 receptor subtype, which are expressed in both neurons and glia of multiple regions within the central nervous system, are a unique class of intracellular proteins that can modulate many biological mechanisms associated with neurodegeneration. These receptors therefore represent compelling putative targets for pharmacologically treating neurodegenerative disorders. In …


Creutzfeldt-Jakob Disease And Alzheimer’S Disease: Does Overlap Of Mechanism Mean Overlap Of Treatment Methods?, David Rotblat Jan 2015

Creutzfeldt-Jakob Disease And Alzheimer’S Disease: Does Overlap Of Mechanism Mean Overlap Of Treatment Methods?, David Rotblat

The Science Journal of the Lander College of Arts and Sciences

Alzheimer’s disease is a neurodegenerative disorder that is the 6th leading cause of death in the United States. More than 5.5 million People over the age of 65 are currently diagnosed with Alzheimer’s disease with predictions of 13.8 million to be diagnosed by the year 2050 (Sultana, et al., 2013) (Hebert, Weuve, Scherr, & Evans, 2013). With few treatments available, scientists are desperately looking for a solution to this growing epidemic. Creutzfeldt-Jakob disease is also a neurodegenerative disorder, but with a far less prevalence of only 4.6 persons per million per year. It was discovered that Alzheimer’s and Creutzfeldt-Jakob disease …


Amyotrophic Lateral Sclerosis (Als) And Spinal Muscular Atrophy (Sma): A Genetic Linkage?, Michael Groden Jan 2015

Amyotrophic Lateral Sclerosis (Als) And Spinal Muscular Atrophy (Sma): A Genetic Linkage?, Michael Groden

The Science Journal of the Lander College of Arts and Sciences

Neurodegenerative motor neuron disorders (MNDs) have devastating effects. Spinal Muscular Atrophy (SMA), for example, is a debilitating and sometimes lethal disease in children. SMA is monogenic, autosomal recessively inherited disorder caused by a loss-of-function mutation of surviving motor neuron 1 (SMN1). SMN2 is an identical copy of this gene and produces abbreviated transcripts without exon 7 though some full transcripts are produced that ameliorate the disease. Previous clinical trials for this disease have not produced consistent results. However, in a recent cross-sectional study, biomarkers for SMA (BforSMA), protein candidates and metabolite markers were identified (Finkel et al., 2012). These markers …